Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.

Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G

Open source

DOI: 10.1200/jco.2017.76.0611
Published: 2018 Apr 1
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.2017.76.0611,
  title = {Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.},
  author = {Grill J and Massimino M and Bouffet E and Azizi AA and McCowage G and Cañete A and Saran F and Le Deley MC and Varlet P and Morgan PS and Jaspan T and Jones C and Giangaspero F and Smith H and Garcia J and Elze MC and Rousseau RF and Abrey L and Hargrave D and Vassal G},
  year = {2018},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco.2017.76.0611},
  url = {https://doi.org/10.1200/jco.2017.76.0611}
}

RIS

TY  - JOUR
TI  - Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
AU  - Grill J
AU  - Massimino M
AU  - Bouffet E
AU  - Azizi AA
AU  - McCowage G
AU  - Cañete A
AU  - Saran F
AU  - Le Deley MC
AU  - Varlet P
AU  - Morgan PS
AU  - Jaspan T
AU  - Jones C
AU  - Giangaspero F
AU  - Smith H
AU  - Garcia J
AU  - Elze MC
AU  - Rousseau RF
AU  - Abrey L
AU  - Hargrave D
AU  - Vassal G
PY  - 2018
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco.2017.76.0611
UR  - https://doi.org/10.1200/jco.2017.76.0611
ER  -

APA

J, G., M, M., E, B., AA, A., G, M., A, C., F, S., MC, L. D., P, V., PS, M., T, J., C, J., F, G., H, S., J, G., MC, E., RF, R., L, A., D, H., & G, V. (2018). Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco.2017.76.0611

Source records

pubmed · retrieved 2026-09-25T04:29:35.142Z
europe-pmc · retrieved 2026-09-25T04:29:35.188Z
hal · retrieved 2026-09-25T04:29:35.210Z